An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Genentech, Inc.13 sites in 2 countries43 target enrollmentMarch 17, 2015

ConditionsBreast Cancer

InterventionsGDC-0927

DrugsGDC-0927

Overview

Phase: Phase 1
Intervention: GDC-0927
Conditions: Breast Cancer
Sponsor: Genentech, Inc.
Enrollment: 43
Locations: 13
Primary Endpoint: Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of GDC-0927
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is an open-label, dose-finding, safety, pharmacokinetics (PK), and evidence-of-activity study of GDC-0927 in postmenopausal women with locally advanced or metastatic Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 (HER2) breast cancer. The study will be conducted in two parts: Dose escalation and Dose expansion. During dose escalation, GDC-0927 will be administered orally as a single dose on Day -7 for PK evaluation during the lead-in period. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 using standard 3+3 design. During dose expansion, there will be no PK week lead-in period. All participants will be treated until disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.

Registry

clinicaltrials.gov

Start Date

March 17, 2015

End Date

January 10, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Genentech, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease, both progressing after at least 6 months of hormonal therapy for ER+ breast cancer
•ER-positive tumor, HER2-negative breast cancer
•No prior treatment with GDC-0810 (allowed only during dose expansion stage)
•No more than 2 prior chemotherapies in the advanced or metastatic setting
•At least 2 months must have elapsed from the use of tamoxifen
•At least 6 months must have elapsed from the use of fulvestrant
•At least 2 weeks must have elapsed from the use of any other endocrine therapy
•At least 3 weeks must have elapsed from the use of any chemotherapy
•Females, 18 years of age or older
•Postmenopausal status as defined by the protocol

Exclusion Criteria

•Untreated or symptomatic brain metastases
•Current treatment with any systemic anti-cancer therapies for advanced disease or any systemic experimental treatment on another clinical trial
•Any of the following within 12 months prior to enrollment: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of Grade greater than or equal to (\>/=) 2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, or cerebrovascular accident including transient ischemic attack
•Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
•Known Human Immunodeficiency Virus (HIV) infection
•Major surgery within 4 weeks prior to enrollment
•Radiation therapy within 2 weeks prior to enrollment

Arms & Interventions

Part I: Dose Escalation - GDC-0927

Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.

Intervention: GDC-0927

Part II: Dose Expansion - GDC-0927

Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.

Intervention: GDC-0927

Outcomes

Primary Outcomes

Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of GDC-0927

Time Frame: Day-7 through Cycle 1 (cycle length: 28 days)

Percentage of Participants With Adverse Events (AEs)

Time Frame: From screening up to approximately 3 years

Secondary Outcomes

Percentage of Participants With Objective Response Assessed by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)(At screening, every 8 weeks from Cycle 1 (each cycle: 28 days) up to end of treatment (up to approximately 3 years))
Part I: Maximum Observed Plasma Concentration (Cmax) of GDC-0927(Pre-dose (0 hour [hr]), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day -7; Days -5, -4, -3; pre-dose (0 hr) on Day 1 Cycle 1; pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8 hrs post-dose on Day 1 Cycle 2 (cycle length: 28 days))
Percentage of Participants With Clinical Benefit Assessed by RECIST v1.1(At screening, every 8 weeks from Cycle 1 (each cycle: 28 days) up to end of treatment (up to approximately 3 years))
Part II: Change From Baseline in QTc Interval Using Fridericia's Formula, as Assessed by ECG(Screening (baseline); Cycle 1 Day 1; Cycle 2 Day 1; end of treatment (up to approximately 3 years) (each cycle = 28 days))
Part II: Cmax of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day 1 Cycle 1; pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8 hrs post-dose on Day 1 Cycle 2 (each cycle: 28 days))
Plasma Half-Life (t1/2) of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day -7; Days -5, -4, -3; pre-dose (0 hr) on Day 1 Cycle 1 (cycle length: 28 days))
Part I: Time to Reach Cmax (Tmax) of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day -7; Days -5, -4, -3; pre-dose (0 hr) on Day 1 Cycle 1; pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8 hrs post-dose on Day 1 Cycle 2 (cycle length: 28 days))
Part II: Tmax of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day 1 Cycle 1; pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8 hrs post-dose on Day 1 Cycle 2 (each cycle: 28 days))
Part I: Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day -7; Days -5, -4, -3; pre-dose (0 hr) on Day 1 Cycle 1; pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8 hrs post-dose on Day 1 Cycle 2 (cycle length: 28 days))
Part II: AUC of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day 1 Cycle 1; pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8 hrs post-dose on Day 1 Cycle 2 (each cycle: 28 days))
Part II: t1/2 of GDC-0927(Pre-dose (0 hr), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs post-dose on Day 1 Cycle 1 (each cycle: 28 days))
Part I: Change From Baseline in RR Interval, as Assessed by ECG(Screening (baseline); Days -7, -5, -4, -3; Cycle 2 Day 1; end of treatment (up to approximately 3 years) (each cycle = 28 days))
Part I: Change From Baseline in Corrected QT (QTc) Interval Using Fridericia's Formula, as Assessed by Electrocardiogram (ECG)(Screening (baseline); Days -7, -5, -4, -3; Cycle 2 Day 1; end of treatment (up to approximately 3 years) (each cycle = 28 days))
Part II: Change From Baseline in RR Interval, as Assessed by ECG(Screening (baseline); Cycle 1 Day 1; Cycle 2 Day 1; end of treatment (up to approximately 3 years) (each cycle = 28 days))